补精解毒方治疗中晚期非小细胞肺癌临床疗效分析

目的：分析补精解毒方治疗中晚期非小细胞肺癌临床疗效。方法：临床上参照《中药新药临床研究指导原则》拟定肺癌诊断与分期标准，选择172例非小细胞肺癌患者，信封法随机分为补精解毒方组与化疗组。补精解毒方组86例口服冬虫夏草、番荔枝子，未用化疗等其它抗癌方法，化疗组86例采用EP或TP方案化疗。观察临床受益率，生存质量，2年总生存率和中位生存期，判定补精解毒方临床疗效。结果：补精解毒方组较化疗组有较高的临床受益率（癌灶稳定率），生存质量（KPS评分治疗前后提高率），两组有显著性差异（P〈0．05）。2年总生存率和中位生存期相近无显著性差异（P〉0．05）。结论：补精解毒方治疗中晚期非小细胞肺癌患者能改善生活质量，2年总生存率和中位生存期与化疗组疗效相近。

Investigate Treatment of Bujing Jiedu for Advanced Non-Small Cell Lung Cancer

Objective：To investigate the treatment of bujing Jiedu for advanced non-small cell lung cancer. Method： 172 cases of non-small cell lung cancer patients were randomly divided into 2 groups according ＂Chinese new drug clinical research guidelines＂ . 86 patients in the bujing Jiedu group take orally Cordyceps, Annona, without cheomotherapys, 86 patients in the chemotherapy group were treated with EP or TP. Oberserve the clinical benefit rate, quality of life, 1 year overall survival rate and mediansurvival. Results ： hujing Jiedu group had a higher clinical benefit rate, quality of life than the chemotherapy group,with the difference in 2 group very significant （ P〈0.05 ）. 2 year overall survival rate and median survival was similar （ P〉0.05 ）. Conclusion ： The treatment of bujingjiedu for advanced non-small cell lung cancer can improve the quality of life. 2-year overall survival and median survival was similar with the chemotherapy group.